Harvard Professor's Attack On Pharma's Clinical Trials Is Absurd

Dr. Marcia Angell, a senior lecturer at Harvard Medical School and the first woman to serve as editor-in-chief of The New England Journal of Medicine, has long been a critic of the pharmaceutical industry. This industry is far from immune to criticism, nor should it be. However, Dr. Angell’s critiques tend to expose her lack of knowledge of the workings of the drug R&D process and the important relationship that exists between academia and industry.